A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
Public ClinicalTrials.gov record NCT05963997. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Open-label Study of Samuraciclib in Combination With Elacestrant in Participants With Metastatic or Locally Advanced Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Breast Cancer
Study identification
- NCT ID
- NCT05963997
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Carrick Therapeutics Limited
- Industry
- Enrollment
- 49 participants
Conditions and interventions
Interventions
- Elacestrant Dihydrochloride Drug
- Samuraciclib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 8, 2023
- Primary completion
- Mar 5, 2026
- Completion
- Mar 5, 2026
- Last update posted
- Mar 22, 2026
2023 – 2026
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 38 - Northwestern University, Feinberg School of Medicine, Northwestern University | Chicago | Illinois | 60611 | — |
| Site 42 - Dana-Farber Cancer Institute, EDDC | Boston | Massachusetts | 02215 | — |
| Site 35 - Cleveland Clinic, Taussig Cancer Institute | Cleveland | Ohio | 44106 | — |
| Site 41 - The START Center for Cancer Care, South Texas Oncology and Hematology | San Antonio | Texas | 78229 | — |
| Site 32 - Swedish Medical Center, Swedish Cancer Institute (SCI),Cherry Hill Campus | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05963997, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05963997 live on ClinicalTrials.gov.